ResMed said revenue for the 3 months ended September 30, 2025 was $1,335.6 million, up 9% from $1,224.5 million in the prior year period (8% on a constant currency basis), and gross margin was 61.5%.

1. 01

   ResMed said revenue for the 3 months ended September 30, 2025 was $1,335.6 million, up 9% from $1,224.5 million in the prior year period (8% on a constant currency basis), and gross margin was 61.5%.

2. 02

   The company said income from operations was $446.5 million, up 15%, and non-GAAP income from operations was $482.1 million, up 19%. It recorded $16 million of restructuring-related charges.

3. 03

   ResMed said net income was $348.5 million and diluted earnings per share was $2.37, while non-GAAP diluted earnings per share was $2.55, up 16% from $2.20 in the prior year period.

4. 04

   The company said operating cash flow for the quarter was $457 million, it paid $88 million in dividends and repurchased 523,000 shares for $150 million. It also declared a quarterly cash dividend of $0.60 per share.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.